Rilmazafone

Synonyms: 利马扎封
Rilmazafone (450191S) 是一种具有口服活性的睡眠诱导剂,靶向细胞色素 P-450b 和细胞色素 P-450e,可在大鼠、小鼠和犬体内诱导肝药酶活性,并可用于失眠相关研究。
产品编号: MS-W42365 CAS No.: 99593-25-6 分子式: C21H20Cl2N6O3 分子量: 475.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Rilmazafone (450191S) 是一种具有口服活性的睡眠诱导剂,靶向细胞色素 P-450b 和细胞色素 P-450e,可在大鼠、小鼠和犬体内诱导肝药酶活性,并可用于失眠相关研究。

生物实验数据

生物活性 Rilmazafone (450191S) is an orally active sleep-inducing agent that targets cytochrome P-450b and cytochrome P-450e, induces hepatic drug-metabolizing enzyme activity in rats, mice, and dogs, and can be used in insomnia-related research.
体内研究
(In Vivo)

Rilmazafone (200-600 mg/kg; p.o.; daily for 3-5 days; single dose) 预处理大鼠可诱导肝脏细胞色素 P-450 依赖性药物代谢酶,从而降低 Rilmazafone 代谢产物的血浆浓度,而单次高剂量会短暂抑制特定肝脏酶的活性。
Rilmazafone (0.3-3 mg/kg; p.o.; single dose) 会对睡眠障碍雄性 Wistar 大鼠产生剂量依赖性催眠作用:在 1 和 3 mg/kg 剂量下可显著缩短睡眠潜伏期;在 3 mg/kg 剂量下可显著减少觉醒时间并增加非快速眼动 (non-REM) 睡眠时间;在 1 和 3 mg/kg 剂量下可显著降低非快速眼动睡眠的 δ 活动;而在所有测试剂量下均不改变快速眼动 (REM) 睡眠时间。

Animal Model: Jcl Sprague-Dawley (adult male, 7-8 weeks old)
Dosage: 200 mg/kg (5-day pretreatment + single dose); 600 mg/kg (3-day pretreatment + 200 mg/kg single dose); 200 mg/kg (single dose, liver collection); 600 mg/kg (3-day pretreatment)
Administration: p.o.; daily for 3 days; daily for 5 days; single dose
Result: Showed plasma levels of metabolite M-1 similar to controls at peak but undetectable by 4 hours post-dose, M-2 plus M-D peaked at 2 hours then decreased rapidly, and M-3 plus M-A peaked between 2-4 hours then decreased rapidly in rats pretreated with 200 mg/kg daily for 5 days followed by 200 mg/kg single dose.
Showed peak plasma levels of all measured metabolites (M-1, M-2 plus M-D, M-3 plus M-A) significantly lower than controls, with M-1 peaking at 15-60 minutes, M-2 plus M-D peaking at 1 hour, and M-3 plus M-A peaking at 2 hours, all declining rapidly thereafter in rats pretreated with 600 mg/kg daily for 3 days followed by 200 mg/kg single dose.
Suppressed hepatic 7-methoxycoumarin O-demethylase activity to 45.1 nmol/min/g liver, a statistically significant reduction compared to controls in rats given a single 200 mg/kg dose with liver collection at 6 hours.
Increased hepatic 7-methoxycoumarin O-demethylase activity to 130.7 nmol/min/g liver, 7-ethoxycoumarin O-deethylase activity to 220.8 nmol/min/g liver, and 7-propoxycoumarin O-depropylase activity to 175.7 nmol/min/g liver, all statistically significant increases compared to controls in rats given 600 mg/kg daily for 3 days.
Animal Model: Wistar rats (male, 240-320 g, sleep disturbance model)
Dosage: 0.3, 1, 3 mg/kg
Administration: p.o.; single dose
Result: Shortened sleep latency to 51.6 min (1 mg/kg) and 48.0 min (3 mg/kg), respectively, compared to control.
Decreased awake time to 198.0 min and increased non-REM sleep time to 139.0 min at 3 mg/kg compared to control.
Showed no significant effects on sleep latency, awake time, or non-REM sleep time at 0.3 mg/kg compared to control.
Caused no significant effects on total REM sleep time at all tested doses compared to control.

化学信息

分子量 475.33
分子式 C21H20Cl2N6O3
CAS No. 99593-25-6
别名 利马扎封

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础